Drug Facts
Composition & Profile
Identifiers & Packaging
16 HOW SUPPLIED/STORAGE AND HANDLING Description NDC Presentation/How Supplied ZILRETTA NDC 65250-003-01 ZILRETTA (triamcinolone acetonide extended-release injectable suspension) single-dose kit. Kit Contents ZILRETTA microsphere powder NDC 65250-001-01 Single-dose vial to deliver 32 mg of triamcinolone acetonide supplied as a sterile, white to off-white powder in a cerium glass (clear) vial with a rubber stopper and an aluminum seal with a gray plastic cap. Diluent NDC 65250-002-01 5 mL single-dose vial supplied as a sterile, colorless to pale yellow, clear liquid solution of 0.9% w/w sodium chloride (normal saline) containing 0.5% w/w sodium carboxymethylcellulose, and 0.1% w/w polysorbate-80 in a glass vial with a rubber stopper, aluminum seal and white plastic cap. Sterile vial adapter STORAGE To maintain expiry period, refrigerate the ZILRETTA single-dose kit 2°-8°C (36°-46°F) before use. If refrigeration is unavailable, store the ZILRETTA single-dose kit in the sealed, unopened kit at temperatures not exceeding 25°C (77°F) for up to three weeks and then discard. Do not expose the ZILRETTA single-dose kit to temperatures above 25°C (77°F). Do not freeze. Store vials in carton.; PRINCIPAL DISPLAY PANEL - Kit Carton NDC 65250-003-01 Rx Only Zilretta ® (triamcinolone acetonide extended-release injectable suspension) 32 mg per vial For intra-articular injection only. Single-dose kit. Discard unused portion. Must be reconstituted with the supplied diluent. This carton contains: 1 vial of Zilretta microsphere powder 1 vial of diluent (5mL) for Zilretta 1 sterile vial adapter PACIRA PHARMACEUTICALS, INC. Principal Display Panel - Kit Carton; PRINCIPAL DISPLAY PANEL - 32 mg Vial Label NDC 65250-001-01 Rx Only Zilretta ® (triamcinolone acetonide extended-release injectable suspension) 32 mg per vial For intra-articular injection only. Must be reconstituted with the supplied diluent. PACIRA PHARMACEUTICALS, INC. Principal Display Panel - 32 mg Vial Label; PRINCIPAL DISPLAY PANEL - 5 mL Vial Label NDC 65250-002-01 Rx Only DILUENT for use with Zilretta ® 5 mL Sterile single-use vial Do not administer directly. PACIRA PHARMACEUTICALS, INC. Principal Display Panel - 5 mL Vial Label
- 16 HOW SUPPLIED/STORAGE AND HANDLING Description NDC Presentation/How Supplied ZILRETTA NDC 65250-003-01 ZILRETTA (triamcinolone acetonide extended-release injectable suspension) single-dose kit. Kit Contents ZILRETTA microsphere powder NDC 65250-001-01 Single-dose vial to deliver 32 mg of triamcinolone acetonide supplied as a sterile, white to off-white powder in a cerium glass (clear) vial with a rubber stopper and an aluminum seal with a gray plastic cap. Diluent NDC 65250-002-01 5 mL single-dose vial supplied as a sterile, colorless to pale yellow, clear liquid solution of 0.9% w/w sodium chloride (normal saline) containing 0.5% w/w sodium carboxymethylcellulose, and 0.1% w/w polysorbate-80 in a glass vial with a rubber stopper, aluminum seal and white plastic cap. Sterile vial adapter STORAGE To maintain expiry period, refrigerate the ZILRETTA single-dose kit 2°-8°C (36°-46°F) before use. If refrigeration is unavailable, store the ZILRETTA single-dose kit in the sealed, unopened kit at temperatures not exceeding 25°C (77°F) for up to three weeks and then discard. Do not expose the ZILRETTA single-dose kit to temperatures above 25°C (77°F). Do not freeze. Store vials in carton.
- PRINCIPAL DISPLAY PANEL - Kit Carton NDC 65250-003-01 Rx Only Zilretta ® (triamcinolone acetonide extended-release injectable suspension) 32 mg per vial For intra-articular injection only. Single-dose kit. Discard unused portion. Must be reconstituted with the supplied diluent. This carton contains: 1 vial of Zilretta microsphere powder 1 vial of diluent (5mL) for Zilretta 1 sterile vial adapter PACIRA PHARMACEUTICALS, INC. Principal Display Panel - Kit Carton
- PRINCIPAL DISPLAY PANEL - 32 mg Vial Label NDC 65250-001-01 Rx Only Zilretta ® (triamcinolone acetonide extended-release injectable suspension) 32 mg per vial For intra-articular injection only. Must be reconstituted with the supplied diluent. PACIRA PHARMACEUTICALS, INC. Principal Display Panel - 32 mg Vial Label
- PRINCIPAL DISPLAY PANEL - 5 mL Vial Label NDC 65250-002-01 Rx Only DILUENT for use with Zilretta ® 5 mL Sterile single-use vial Do not administer directly. PACIRA PHARMACEUTICALS, INC. Principal Display Panel - 5 mL Vial Label
Overview
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is a microsphere formulation of triamcinolone acetonide, a corticosteroid, to be administered by intra-articular injection. ZILRETTA is formulated in 75:25 poly(lactic-co-glycolic acid) (PLGA) microspheres with a nominal drug load of 25% (w/w) and is provided as a sterile white to off-white powder. ZILRETTA is prepared with a supplied diluent containing an isotonic, sterile, aqueous solution of sodium chloride (NaCl; 0.9% w/w), sodium carboxymethylcellulose (CMC; 0.5% w/w), polysorbate-80 (0.1% w/w) and with sodium hydroxide (NaOH) and hydrochloric acid (HCl) as pH adjusters, as required to form a 5 mL sterile suspension intended for intra-articular injection. Active Ingredient The chemical name for triamcinolone acetonide is 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene- 3,20-dione cyclic 16,17-acetal with acetone. Its structural formula is: MW 434.50 with a molecular formula of C 24 H 31 FO 6 Triamcinolone acetonide occurs as a white to almost white, crystalline powder having not more than a slight odor and is practically insoluble in water and very soluble in alcohol. Each vial of ZILRETTA powder contains 40 mg of triamcinolone acetonide in 160 mg of microspheres, resulting in 32 mg of deliverable triamcinolone acetonide when prepared according to the Instructions for Use. Chemical Structure
Indications & Usage
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. ZILRETTA is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. ( 1 ) Limitation of Use The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated. ( 2.1 ) Limitation of Use The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated. [see Dosage and Administration (2.1) ] .
Dosage & Administration
32 mg (5 mL) administered as a single intra-articular injection in the knee. ( 2.1 ) See Instructions for Use (IFU) for instructions on reconstitution of ZILRETTA with the supplied diluent. ( 2.2 ) It is normal for some residue to be left behind on the vial walls after withdrawing the suspension. ( 2.2 ) ZILRETTA is NOT substitutable with other formulations of injectable triamcinolone acetonide. ( 2.3 ) 2.1 Important Dosage and Administration Information ZILRETTA is administered as a single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). ZILRETTA is for intra-articular use only. Do NOT administer by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous. ZILRETTA is not suitable for use in small joints, such as the hand. The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated [see Adverse Reactions (6) and Nonclinical Toxicology (13.2) ] . The efficacy and safety of ZILRETTA for management of osteoarthritis pain of shoulder and hip have not been evaluated. 2.2 Preparation and Administration of Intra-Articular Suspension Refer to the Instructions for Use for directions on the preparation and administration of ZILRETTA. ZILRETTA is supplied as a single-dose kit containing a vial of ZILRETTA microsphere powder, a vial of sterile diluent, and a sterile vial adapter. ZILRETTA must be prepared using the diluent supplied in the kit. Preparation of ZILRETTA requires close attention to the Instructions for Use to ensure successful administration. Use proper aseptic technique throughout the dose preparation and administration procedure. ZILRETTA is a suspension product and it is normal for some residue to be left behind on the vial walls after withdrawing the contents. Promptly inject ZILRETTA after preparation to avoid settling of the suspension. If needed, the ZILRETTA suspension can be stored in the vial for up to 4 hours at ambient conditions. Gently swirl the vial to resuspend any of the settled microspheres prior to preparing the syringe for injection. The usual technique for intra-articular injection should be followed. Aspiration of synovial fluid may be performed based on clinical judgment prior to administration of ZILRETTA. 2.3 Non-Interchangeability with Other Formulations of Triamcinolone Acetonide for Intra-articular Use ZILRETTA is NOT substitutable with other formulations of injectable triamcinolone acetonide.
Warnings & Precautions
Intra-articular Use Only : Do not administer ZILRETTA by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ( 5.1 ) Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration : Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use. ( 5.2 ) Hypersensitivity Reactions : Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care upon occurrence of an anaphylactic reaction. ( 5.3 ) Joint Infection and Damage : May cause joint pain accompanied by joint swelling. If this occurs, conduct appropriate evaluation to exclude septic arthritis and institute appropriate antimicrobial therapy if septic arthritis is confirmed. ( 5.4 ) 5.1 Warnings and Precautions Specific for ZILRETTA ZILRETTA has not been evaluated and should not be administered by the following routes: Epidural Intrathecal Intravenous Intraocular Intramuscular Intradermal Subcutaneous [see Warnings and Precautions (5.2) ]. 5.2 Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke [see Adverse Reactions (6) ] . These serious neurologic events have been reported with and without use of fluoroscopy. Reports of serious medical events have been associated with the intrathecal route of corticosteroid administration [see Adverse Reactions (6) ] . The safety and effectiveness of epidural and intrathecal administration of corticosteroids have not been established, and corticosteroids are not approved for this use. In particular, the formulation of ZILRETTA should not be considered safe to use for epidural or intrathecal administration. 5.3 Hypersensitivity Reactions Rare instances of anaphylaxis have occurred in patients with hypersensitivity to corticosteroids. Cases of serious anaphylaxis, including death, have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration [see Adverse Reactions (6) ] . Institute appropriate care upon occurrence of an anaphylactic reaction. 5.4 Joint Infection and Damage Intra-articular injection of corticosteroid may be complicated by joint infection. A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and a diagnosis of septic arthritis is confirmed, institute appropriate antimicrobial therapy [see Adverse Reactions (6) ] . Avoid injection of a corticosteroid into an infected site. Local injection of a corticosteroid into a previously infected joint is not usually recommended. Examine any joint fluid present to exclude a septic process. Corticosteroid injection into unstable joints is generally not recommended. Intra-articular injection may result in damage to joint tissues. 5.5 Increased Risk of Infections Intra-articularly injected corticosteroids are systemically absorbed. Patients who are on corticosteroids are more susceptible to infections than are healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used. Infection with any pathogen (viral, bacterial, fungal, protozoan, or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current infection. Advise patients to inform their health care provider if they develop fever or other signs or symptoms of infection. Advise patients who have not been vaccinated to avoid exposure to chicken pox or measles. Instruct patients to contact their health care provider immediately if they are exposed [see Patient Counseling Information (17) ] . 5.6 Alterations in Endocrine Function Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with the potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period (as in trauma, surgery, or illness), institute corticosteroid replacement therapy. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. 5.7 Cardiovascular Effects Corticosteroids can cause elevations of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with synthetic derivatives. Monitor patients with congestive heart failure or hypertension for signs of edema, weight gain, and imbalance in serum electrolytes. Dietary salt restriction and potassium supplementation may be necessary. 5.8 Renal Effects Corticosteroids can cause salt and water retention, and increased excretion of potassium. These effects are less likely to occur with synthetic derivatives. All corticosteroids increase calcium excretion. Monitor patients with renal insufficiency for signs of edema, weight gain, and imbalance in serum electrolytes. Dietary salt restriction and potassium supplementation may be necessary. 5.9 Increased Intraocular Pressure Corticosteroid use may be associated with development or exacerbation of increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment. 5.10 Gastrointestinal Perforation Corticosteroid administration is associated with increased risk of gastrointestinal perforation in patients with certain GI disorders such as active or latent peptic ulcers, diverticulosis, diverticulitis, ulcerative colitis and in patients with fresh intestinal anastomoses. Avoid corticosteroids in these patients because signs of peritoneal irritation following gastrointestinal perforation may be minimal or absent. 5.11 Alterations in Bone Density Corticosteroids decrease bone formation and increase bone resorption through their effect on calcium regulation and inhibition of osteoblast function. Special consideration should be given to patients with or at increased risk of osteoporosis (e.g., postmenopausal women) before initiating corticosteroid therapy. 5.12 Behavioral and Mood Disturbances Corticosteroid use may be associated with new or aggravated adverse psychiatric reactions ranging from euphoria, insomnia, mood swings, and personality changes to severe depression and frank psychotic manifestations. Special consideration should be given to patients with previous or current emotional instability or psychiatric illness before initiating corticosteroid therapy. Advise patients and/or caregivers to immediately report any new or worsening behavior or mood disturbances to their health care provider.
Contraindications
ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product [see Warnings and Precautions (5.3) and How Supplied/Storage and Handling (16) ] . Patients with hypersensitivity to triamcinolone acetonide or any component of the product. ( 4 )
Adverse Reactions
The following serious adverse reactions are described elsewhere in the labeling. Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration [see Warnings and Precautions (5.2) ] Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] Joint Infection and Damage [see Warnings and Precautions (5.4) ] Increased Risk of Infections [see Warnings and Precautions (5.5) ] Alterations in Endocrine Function [see Warnings and Precautions (5.6) ] Cardiovascular Effects [see Warnings and Precautions (5.7) ] Renal Effects [see Warnings and Precautions (5.8) ] Increased Intraocular Pressure [see Warnings and Precautions (5.9) ] Gastrointestinal Perforation [see Warnings and Precautions (5.10) ] Alternations in Bone Density [see Warnings and Precautions (5.11) ] Behavioral and Mood Disturbances [see Warnings and Precautions (5.12) ] Most commonly reported adverse reactions (incidence ≥1%) in clinical studies include sinusitis, cough, and contusions. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pacira Pharmaceuticals, Inc. at 1-844-353-9466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data below reflect exposure to a single 32 mg intra-articular injection of ZILRETTA in clinical studies in patients with moderate to severe pain due to osteoarthritis of the knee. Clinical studies included randomized, double-blind, parallel-group, placebo and/or active-controlled, and pharmacokinetic/pharmacodynamic studies with follow-up ranging from 6-24 weeks. A total of 424 patients received ZILRETTA and 262 received placebo. Treatment emergent adverse reactions reported by greater than or equal to 1% of patients in the ZILRETTA arms are summarized below ( Table 1 and 2 ). Overall, the incidence and nature of adverse reactions was similar to that observed with placebo. Table 1: Most Commonly Reported Treatment-Emergent Adverse Reactions with ZILRETTA (Incidence ≥1%) in Patients with Osteoarthritis of the Knee Preferred Term (MedDRA) ZILRETTA (N=424) Placebo (N=262) Sinusitis 2% 1% Cough 2% 1% Contusions 2% 1% Table 2: Most Commonly Reported Treatment-Emergent Injected Knee Adverse Reactions with ZILRETTA (Incidence ≥1%) in Patients with Osteoarthritis of the Knee Preferred Term (MedDRA) ZILRETTA (N=424) Placebo (N=262) Joint Swelling 3% 2% Contusions 2% 1% The safety of repeat administration of ZILRETTA was evaluated in a multicenter, open-label, single-arm study in patients with osteoarthritis pain of the knee. A total of 179 patients received a repeat injection on or after Week 12 (median 16.6 weeks) and were followed for 52 weeks from the initial injection. As assessed by adverse event rates for the periods of baseline to second dose and second dose to the comparable period after the second dose, there were higher rates of reported mild to moderate arthralgia after the second dose (16%) than after the first dose (6%). The data from this study are insufficient to fully characterize the safety of repeat administration of ZILRETTA. [See also Nonclinical Toxicology (13.2) ]. 6.2 Post-marketing Experience The following adverse reactions, presented alphabetically by body system, have been identified during post-approval use of ZILRETTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Endocrine : Increased blood glucose (in diabetic patients). General and administration site conditions : Pain including injection site pain or discomfort and leg pain. Immune system : Hypersensitivity reactions including pruritus, rash, angioedema, and anaphylaxis [see Contraindications (4) , Warnings and Precautions (5.3) ] . Infections and Infestations : Septic arthritis [see Warning and Precautions (5.4) ] . Musculoskeletal : Arthralgia, joint swelling or effusion, muscle spasms. Nervous system : Headache. Reproductive system : Postmenopausal vaginal bleeding (similar to a menstrual period). Skin and Subcutaneous Tissue : Pruritus. 6.3 Corticosteroid Adverse Reactions The following adverse reactions, presented alphabetically by body system, are from voluntary reports or clinical studies of corticosteroids. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Anaphylactic reactions : Anaphylaxis including death, angioedema [see Warnings and Precautions (5.3) ] . Cardiovascular : Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, hypertension [see Warnings and Precautions (5.7) ] , fat embolism, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic : Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, lupus erythematosus-like lesions, purpura, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine : Decreased carbohydrate and glucose tolerance, development of Cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and electrolyte disturbances : Congestive heart failure in susceptible patients [see Warnings and Precautions (5.7) ] , fluid retention, sodium retention. Gastrointestinal : Abdominal distention, bowel/bladder dysfunction (after intrathecal administration) [see Warnings and Precautions (5.2) ] , elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease) [see Warnings and Precautions (5.10) ] , ulcerative esophagitis. Metabolic : Negative nitrogen balance due to protein catabolism. Musculoskeletal : Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intralesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, post injection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures. Neurologic/Psychiatric : Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychiatric disorders [see Warnings and Precautions (5.12) ] , vertigo. Arachnoiditis, meningitis, paraparesis/paraplegia, and sensory disturbances have occurred after intrathecal administration. Spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke (including brainstem) have been reported after epidural administration of corticosteroids [see Warnings and Precautions (5.2) ] . Ophthalmic : Exophthalmos, glaucoma, increased intraocular pressure [see Warnings and Precautions (5.9) ] , posterior subcapsular cataracts, rare instances of blindness associated with periocular injections. Other : Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain.
Drug Interactions
No drug-drug interaction studies have been conducted with ZILRETTA. Table 3 contains drug interactions associated with systemic corticosteroids. Table 3: Drug Interactions Associated with Systemic Corticosteroids Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), observe patients closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agents at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, monitor coagulation indices frequently to maintain the desired anticoagulant effect. Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs Serum concentrations of isoniazid may be decreased. CYP 3A4 inducers (e.g., barbiturates, phenytoin, carbamazepine, and rifampin) Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of corticosteroids and require that the dosage of corticosteroid be increased. CYP 3A4 inhibitors (e.g., ketoconazole) Ketoconazole, a strong CYP3A4 inhibitor, has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. Cholestyramine Cholestyramine may increase the clearance of corticosteroids. Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Digitalis glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Estrogens, including oral contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Nonsteroidal anti-inflammatory drugs (NSAIDs) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Skin tests Corticosteroids may suppress reactions to allergy related skin tests. Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. If possible, defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued.
Storage & Handling
STORAGE To maintain expiry period, refrigerate the ZILRETTA single-dose kit 2°-8°C (36°-46°F) before use. If refrigeration is unavailable, store the ZILRETTA single-dose kit in the sealed, unopened kit at temperatures not exceeding 25°C (77°F) for up to three weeks and then discard. Do not expose the ZILRETTA single-dose kit to temperatures above 25°C (77°F). Do not freeze. Store vials in carton.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.